Imprimis Pharmaceuticals Inc (IMMY) 7.50 $IMMY
Nasdaq stocks posting largest percentage increases
AP - Tue Jul 29, 12:30PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Imprimis Pharmaceuticals' Go Dropless(TM) Cataract Surgery Formulations to be Featured in Two Sessions at the 2014 American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium
PR Newswire - Thu Jul 24, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, announced today that two Key Opinion Leader (KOL) presentations that describe the benefits of dropless cataract surgery formulations will be delivered at the upcoming American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium in Deer Valley, Utah from July 24 - 27, 2014.
Imprimis Pharmaceuticals Go Dropless(TM) Video Interview Survey Reveals 95% of Leading Cataract Surgeons Surveyed Would Prefer Dropless Therapy
PR Newswire - Tue Jun 24, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq:IMMY), a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients at accessible prices, today unveiled the results of a recent survey1 of leading national cataract surgeons (www.GoDropless.com/why-go-dropless).
Imprimis Pharmaceuticals to Exhibit Go Dropless(TM) Cataract Surgery Formulations at 2014 Kiawah Eye Meeting
PR Newswire - Wed May 28, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients at accessible prices, announced today its attendance at the upcoming 2014 Kiawah Eye Meeting (http://www.healio.com/meeting/kiawaheye) in Kiawah Island, SC, May 29-31, 2014.
Imprimis Pharmaceuticals Scheduled to Present at 13th Annual Needham Healthcare Conference
PR Newswire - Tue Mar 25, 5:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 3:40 p.m. ET. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies, and the institutions who invest in the sector.
Imprimis Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
PR Newswire - Tue Mar 04, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to participate at two growth investor conferences during the month of March.
Biotech Sector Performance February 2014: Red Hot But...
at The Street - Sat Mar 01, 11:01AM CST
An epic month of biotech stock performance ends with a significant sell off.
Imprimis Pharmaceuticals' Pre-Commercial Ophthalmic Formulations to be Presented at 2014 American-European Congress of Ophthalmic Surgery (ACOS(TM))/Dulaney Winter Meeting
PR Newswire - Tue Feb 25, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that James Lewis, MD (http://cataractphiladelphia.com), will present "Dropless Cataract Surgery" during the New Technologies Session of the American-European Congress of Ophthalmic Surgery (ACOS(TM)). The society's Winter Meeting is being held February 23-26, 2014, in Aspen, Colorado. This will be the first time clinical data and clinical experience with Imprimis' dropless cataract surgery formulations and related administration techniques will be presented at a U.S. clinical meeting. ACOS (http://acosurgery.org) represents and educates surgeons, innovators, and industry leaders who have made a significant contribution to the field of ophthalmology.
Imprimis elects Randle House as VP of Pharmacy Operations
M2 - Thu Feb 20, 5:15AM CST
US-based specialist pharmaceutical company Imprimis Pharmaceuticals Inc (IMMY:NasdaqCM) reported on Wednesday the appointment of Randle House as vice president (VP) of its Pharmacy Operations.
Imprimis Pharmaceuticals Names Pharmacy Business Leader Randle House as Vice President of Pharmacy Operations
PR Newswire - Wed Feb 19, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations, today announced that Randle House has joined the company as Vice President of Pharmacy Operations. In this role, House will head the Company's distribution and operations team to make and distribute its patent-pending proprietary drug formulations and other novel pharmaceutical solutions.
Imprimis Pharmaceuticals Announces Acquisition of Pharmacy Creations, Empowering Company to Make and Distribute its Patent-Pending Proprietary Formulations
PR Newswire - Tue Feb 11, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations, today announced that it has come to an agreement to acquire Pharmacy Creations LLC (www.pharmacycreations.com), a premier, state-of-the-art compounding pharmacy located in Randolph, New Jersey. This acquisition would permit the Company to make and distribute its patent-pending proprietary drug formulations and other novel pharmaceutical solutions.
Imprimis Pharmaceuticals to Exhibit Pre-Commercial Ophthalmic Formulations At 2014 ACES/SEE Caribbean Eye Meeting
PR Newswire - Tue Jan 28, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that it will be attending the ACES/SEE Caribbean Eye Meeting (http://caribbeaneyemeeting.com/) in Cancun, Mexico, January 31 to February 4, 2014. Imprimis will continue its Go Dropless(TM) campaign (http://dropless.com/), which has been created to inform ophthalmologists about dropless eye surgery and the injectable compounded drug formulations Imprimis has developed in conjunction with physicians and pharmacists.
OTC Daily Alert Stock Watch - Imprimis Pharmaceuticals, Inc (NASDAQ: IMMY)
WorldStockWire - Fri Aug 30, 12:30AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
PR Newswire - Wed Aug 28, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which is focused on the commercialization of drug formulations through a growing proprietary network of compounding pharmacy relationships and by utilizing the FDA 505(b)(2) development pathway, has announced it has acquired intellectual property, including a provisional patent application, related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents. Imprimis believes this formulation has the potential to significantly impact the fast-growing $5 billion global cataract surgery drug market. The acquisition allows Imprimis to pursue the commercial development of certain proprietary innovations and also provides Imprimis with a preemptive right on additional Novel Drug Solutions and Eye Care Northwest intellectual property and drug development opportunities.
Imprimis Pharmaceuticals, Inc. Comments on Delay in Phase III Impracor(TM) Program
PR Newswire - Mon Aug 12, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of drug formulations utilizing the FDA 505(b)(2) drug development pathway, today announced that last week it was notified by its contract manufacturing supplier, DPT Laboratories, Ltd. ("DPT"
, that its recently produced placebo formulation batch failed, and its active batch showed a lower than expected specification result. As a result, Imprimis announced that there would likely be a delay in the initiation of its Impracor Phase III topical NSAID program. Imprimis is awaiting the receipt of the full CMC report to evaluate its options regarding these manufacturing issues.
Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
PR Newswire - Mon Aug 05, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) drug development pathway, today announced CEO Mark L. Baum will present at the Southern California Investor Conference on August 8, 2013 at the Island Hotel in Newport Beach, CA. The Imprimis presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT. in Room 2.
Nasdaq stocks posting largest percentage increases
AP - Tue Jul 29, 12:30PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Imprimis Pharmaceuticals' Go Dropless(TM) Cataract Surgery Formulations to be Featured in Two Sessions at the 2014 American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium
PR Newswire - Thu Jul 24, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, announced today that two Key Opinion Leader (KOL) presentations that describe the benefits of dropless cataract surgery formulations will be delivered at the upcoming American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium in Deer Valley, Utah from July 24 - 27, 2014.
Imprimis Pharmaceuticals Go Dropless(TM) Video Interview Survey Reveals 95% of Leading Cataract Surgeons Surveyed Would Prefer Dropless Therapy
PR Newswire - Tue Jun 24, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq:IMMY), a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients at accessible prices, today unveiled the results of a recent survey1 of leading national cataract surgeons (www.GoDropless.com/why-go-dropless).
Imprimis Pharmaceuticals to Exhibit Go Dropless(TM) Cataract Surgery Formulations at 2014 Kiawah Eye Meeting
PR Newswire - Wed May 28, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients at accessible prices, announced today its attendance at the upcoming 2014 Kiawah Eye Meeting (http://www.healio.com/meeting/kiawaheye) in Kiawah Island, SC, May 29-31, 2014.
Imprimis Pharmaceuticals Scheduled to Present at 13th Annual Needham Healthcare Conference
PR Newswire - Tue Mar 25, 5:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 3:40 p.m. ET. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies, and the institutions who invest in the sector.
Imprimis Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
PR Newswire - Tue Mar 04, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to participate at two growth investor conferences during the month of March.
Biotech Sector Performance February 2014: Red Hot But...
at The Street - Sat Mar 01, 11:01AM CST
An epic month of biotech stock performance ends with a significant sell off.
Imprimis Pharmaceuticals' Pre-Commercial Ophthalmic Formulations to be Presented at 2014 American-European Congress of Ophthalmic Surgery (ACOS(TM))/Dulaney Winter Meeting
PR Newswire - Tue Feb 25, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that James Lewis, MD (http://cataractphiladelphia.com), will present "Dropless Cataract Surgery" during the New Technologies Session of the American-European Congress of Ophthalmic Surgery (ACOS(TM)). The society's Winter Meeting is being held February 23-26, 2014, in Aspen, Colorado. This will be the first time clinical data and clinical experience with Imprimis' dropless cataract surgery formulations and related administration techniques will be presented at a U.S. clinical meeting. ACOS (http://acosurgery.org) represents and educates surgeons, innovators, and industry leaders who have made a significant contribution to the field of ophthalmology.
Imprimis elects Randle House as VP of Pharmacy Operations
M2 - Thu Feb 20, 5:15AM CST
US-based specialist pharmaceutical company Imprimis Pharmaceuticals Inc (IMMY:NasdaqCM) reported on Wednesday the appointment of Randle House as vice president (VP) of its Pharmacy Operations.
Imprimis Pharmaceuticals Names Pharmacy Business Leader Randle House as Vice President of Pharmacy Operations
PR Newswire - Wed Feb 19, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations, today announced that Randle House has joined the company as Vice President of Pharmacy Operations. In this role, House will head the Company's distribution and operations team to make and distribute its patent-pending proprietary drug formulations and other novel pharmaceutical solutions.
Imprimis Pharmaceuticals Announces Acquisition of Pharmacy Creations, Empowering Company to Make and Distribute its Patent-Pending Proprietary Formulations
PR Newswire - Tue Feb 11, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations, today announced that it has come to an agreement to acquire Pharmacy Creations LLC (www.pharmacycreations.com), a premier, state-of-the-art compounding pharmacy located in Randolph, New Jersey. This acquisition would permit the Company to make and distribute its patent-pending proprietary drug formulations and other novel pharmaceutical solutions.
Imprimis Pharmaceuticals to Exhibit Pre-Commercial Ophthalmic Formulations At 2014 ACES/SEE Caribbean Eye Meeting
PR Newswire - Tue Jan 28, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that it will be attending the ACES/SEE Caribbean Eye Meeting (http://caribbeaneyemeeting.com/) in Cancun, Mexico, January 31 to February 4, 2014. Imprimis will continue its Go Dropless(TM) campaign (http://dropless.com/), which has been created to inform ophthalmologists about dropless eye surgery and the injectable compounded drug formulations Imprimis has developed in conjunction with physicians and pharmacists.
OTC Daily Alert Stock Watch - Imprimis Pharmaceuticals, Inc (NASDAQ: IMMY)
WorldStockWire - Fri Aug 30, 12:30AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
PR Newswire - Wed Aug 28, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which is focused on the commercialization of drug formulations through a growing proprietary network of compounding pharmacy relationships and by utilizing the FDA 505(b)(2) development pathway, has announced it has acquired intellectual property, including a provisional patent application, related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents. Imprimis believes this formulation has the potential to significantly impact the fast-growing $5 billion global cataract surgery drug market. The acquisition allows Imprimis to pursue the commercial development of certain proprietary innovations and also provides Imprimis with a preemptive right on additional Novel Drug Solutions and Eye Care Northwest intellectual property and drug development opportunities.
Imprimis Pharmaceuticals, Inc. Comments on Delay in Phase III Impracor(TM) Program
PR Newswire - Mon Aug 12, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of drug formulations utilizing the FDA 505(b)(2) drug development pathway, today announced that last week it was notified by its contract manufacturing supplier, DPT Laboratories, Ltd. ("DPT"
, that its recently produced placebo formulation batch failed, and its active batch showed a lower than expected specification result. As a result, Imprimis announced that there would likely be a delay in the initiation of its Impracor Phase III topical NSAID program. Imprimis is awaiting the receipt of the full CMC report to evaluate its options regarding these manufacturing issues. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
PR Newswire - Mon Aug 05, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) drug development pathway, today announced CEO Mark L. Baum will present at the Southern California Investor Conference on August 8, 2013 at the Island Hotel in Newport Beach, CA. The Imprimis presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT. in Room 2.
